Jiangsu Simcere Pharmaceutical Co., Ltd.
82
14
18
25
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
3.7%
3 terminated/withdrawn out of 82 trials
89.3%
+2.8% vs industry average
24%
20 trials in Phase 3/4
4%
1 of 25 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (82)
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Role: lead
Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors
Role: lead
the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib
Role: collaborator
First in Human Study of SIM0610 in Solid Tumors
Role: lead
A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
Role: lead
An Open-Label Drug Interaction Clinical Study to Evaluate Itraconazole, Rifampin, Midazolam and SIM0270 in Chinese Healthy Adult Participants
Role: lead
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of SIM0811 Injection in Healthy Chinese Adult Subjects
Role: lead
A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions
Role: lead
Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Role: collaborator
A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors
Role: lead
A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic Dermatitis
Role: lead
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
Role: lead
To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SIM0278 in Chinese Healthy Subjects
Role: lead
A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer
Role: lead
Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0348 in Advanced Solid Tumors
Role: lead
A Phase I Study of SIM0686 in Participants With Locally Advanced/Metastatic Solid Tumors
Role: lead
A Phase I Study of SIM0388 in Participants With Malignant Ascites.
Role: lead
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC
Role: lead
Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors
Role: lead
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors
Role: lead